Dividend Overview
Dividend Yield
—
Dividend / Share
—
Altimmune Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.
Did you know?
Currently operating at a negative 244702.8% profit margin.
Current Price
$2.82
+8.46%GoodMoat Value
$0.00
99.9% overvaluedProfile
Valuation (TTM)
Market Cap$294.00M
P/E-3.34
EV—
P/B1.31
Shares Out104.25M
P/Sales8166.58
Revenue$36000.00
EV/EBITDA—
Altimmune Inc (ALT) Dividends
Key Metrics
Market Cap
$294.00M
P/E Ratio
-3.34
Forward P/E
—
EPS
$-1.00
PEG Ratio
0.16
Book Value
$2.16
Dividend Yield
—
Profit Margin
-244702.78%
ROE
-39.17%
Dividend History
Dividend Safety
ALT Dividend Analysis
Altimmune Inc (ALT) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: -3.34. Profit margin: -244702.78%. Free cash flow: $-67.55M. This page shows Altimmune Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Altimmune Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.